Spectrum of Clostridium difficile infections: Particular clinical situations

Bouza, Emilio; Vecchio, Marcela González del; Reigadas, Elena

doi:10.1016/j.anaerobe.2015.12.005

Cited by 4 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excluding two neonates, two infants (5 months and 19 months), and one 3-year-old child, the mean age (±standard deviation) was 56.1 ± 19.7 years (range, 12–88 years). Concerning infants or neonates, they may have inflammatory intestinal conditions favoring CDI [40], [41]. About 47% (28/60) of the described patients are over sixty and among them 35% (21/60) are between 60 and 79 years old.…”

Section: Systematic Reviewmentioning

confidence: 99%

Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature

Doufair

Eckert

Drieux

et al. 2017

IDCases

View full text Add to dashboard Cite

We report two cases of bacteremia due to Clostridium difficile from two French hospitals. The first patient with previously diagnosed rectal carcinoma underwent courses of chemotherapy, and antimicrobial treatment, and survived the C. difficile bacteremia. The second patient with colon perforation and newly diagnosed lung cancer underwent antimicrobial treatment in an ICU but died shortly after the episode of C. difficile bacteremia. A review of the literature allowed the identification of 137 cases of bacteremia between July 1962 and November 2016. Advanced age, gastro-intestinal disruption, severe underlying diseases and antimicrobial exposure were the major risk factors for C. difficile bacteremia. Antimicrobial therapy was primarily based on metronidazole and/or vancomycin. The crude mortality rate was 35% (21/60).

show abstract

Section: Systematic Reviewmentioning

confidence: 99%

Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature

Doufair

Eckert

Drieux

et al. 2017

IDCases

View full text Add to dashboard Cite

show abstract

Clostridium difficile : A rare cause of pyogenic liver abscess

et al. 2016

View full text Add to dashboard Cite

The Impact of Actotoxumab Treatment of Gnotobiotic Piglets Infected With Different Clostridium difficile Isogenic Mutants

Danz

Lee

Chapman-Bonofiglio

et al. 2019

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Nosocomial infections with Clostridium difficile are on the rise in the Unites States, attributed to emergence of antibiotic-resistant and hypervirulent strains associated with greater likelihood of recurrent infections. In addition to antibiotics, treatment with Merck anti-toxin B (TcdB) antibody bezlotoxumab is reported to reduce recurrent infections. However, treatment with anti-toxin A (TcdA) antibody actotoxumab was associated with dramatically increased disease severity and mortality rates in humans and gnotobiotic piglets. Using isogenic mutants of C. difficile strain NAPI/BI/027 deficient in TcdA (A−B+) or TcdB (A+B−), and the wild type, we investigated how and why treatment of infected animals with anti-TcdA dramatically increased disease severity. Contrary to the hypothesis, among piglets treated with anti-TcdA, those with A+B− infection were disease free, in contrast to the disease enhancement seen in those with wild-type or A−B+ infection. It seems that the lack of TcdA, through either deletion or neutralization with anti-TcdA, reduces a competitive pressure, allowing TcdB to freely exert its profound effect, leading to increased mucosal injury and disease severity.

show abstract

Spectrum of Clostridium difficile infections: Particular clinical situations

Cited by 4 publications

References 69 publications

Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature

Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature

Clostridium difficile : A rare cause of pyogenic liver abscess

The Impact of Actotoxumab Treatment of Gnotobiotic Piglets Infected With Different Clostridium difficile Isogenic Mutants

Contact Info

Product

Resources

About